Author

W. Higashide

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Approach:deep learning· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

P. R. Spilman· 4 shared P. Soon-Shiong· 4 shared S. Tanaka· 4 shared J. Taft· 3 shared K. Niazi· 3 shared M. Martin-Fernandez· 3 shared S. Rabizadeh· 3 shared A. Rice· 2 shared

Activity by Year

2021-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

P. R. Spilman

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Heteologous saRNA-Prime, DNA Dual-Antigen-Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

A. Rice, M. Verma, E. Voigt, P. Battisti, S. Beaver, S. Reed, K. Dinkins, S. Mody, L. Zakin, S. Tanaka, B. Morimoto, W. Higashide, C. A. Olson, E. R. Gabitzsch, J. T. Safrit, , P. Soon-Shiong

This study evaluates heterologous vaccination with two SARS-CoV-2 vaccines in mice, finding enhanced humoral and T-cell responses and broad neutralizing activity against variants.

bioRxiv · Nov 29, 2021 · PreprintImmunology

Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display

S. Tanaka, C. A. Olson, C. O. Barnes, W. Higashide, M. Gonzales, J. Taft, A. Richardson, M. Martin-Fernandez, D. Bogunovic, P. N. P. Gnanapragasam, P. Bjorkman, P. R. Spilman, K. Niazi, S. Rabizadeh, P. Soon-Shiong

This study uses mRNA display to identify and engineer neutralizing antibodies against SARS-CoV-2 variants, revealing binding modes and demonstrating their effectiveness against mutations in the spike protein.

bioRxiv · Sep 14, 2021Immunology

The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice

A. Rice, M. Verma, A. Shin, L. Zakin, P. Sieling, S. Tanaka, J. Balint, K. Dinkins, H. Adisetiyo, B. Morimoto, W. Higashide, J. Taft, R. S. Patel, S. Buta, M. Martin-Fernandez, , P. Soon-Shiong

This study evaluates a dual-antigen Ad5 vaccine delivered via subcutaneous and intranasal routes in mice, showing that combined prime-only delivery elicits strong humoral and T-cell responses against SARS-CoV-2.

bioRxiv · Mar 22, 2021Immunology

A recombinant ACE2 Triple Decoy that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variants

S. Tanaka, G. Nelson, A. Olson, O. Buzko, W. Higashide, A. Shin, M. Gonzales, J. Taft, R. S. Patel, S. Buta, M. Martin-Fernandez, D. S. Bogunovic, P. R. Spilman, K. Niazi, S. Rabizadeh, P. Soon-Shiong

The paper develops an ACE2 Triple Decoy that maintains high affinity for SARS-CoV-2 variants and shows enhanced affinity for specific mutations.

bioRxiv · Mar 9, 2021Bioengineering